Patient characteristics and their impact on the detection of H-Y antigen–specific antibodies at 3 months posttransplant
| . | N . | Any HY-Ab seropositivity 3 mo post-HCT, n (%) . | HY-Ab seronegativity 3 mo post-HCT, n (%) . | P . |
|---|---|---|---|---|
| Total cohort | 136 | 78 (57%) | 58 (42%) | |
| Patient age, y | ||||
| <50 | 58 | 31 (40%) | 27 (47%) | .49 |
| ≥50 | 78 | 47 (60%) | 31 (53%) | |
| Donor age, y | ||||
| <50 | 92 | 50 (64%) | 42 (72%) | .46 |
| ≥50 | 43 | 27 (35%) | 16 (28%) | |
| Missing | 1 | |||
| Disease | ||||
| AML | 38 | 23 (29%) | 15 (26%) | .79 |
| ALL | 26 | 16 (21%) | 10 (17%) | |
| MDS, MPN | 19 | 12 (15%) | 7 (12%) | |
| Lymphoma | 48 | 25 (32%) | 23 (40%) | |
| Others | 5 | 2 (3%) | 3 (5%) | |
| Disease risk | ||||
| Standard | 105 | 57 (73%) | 48 (83%) | .22 |
| High | 31 | 21 (27%) | 10 (17%) | |
| CMV seropositivity | ||||
| D+R+ | 52 | 27 (35%) | 25 (43%) | .15 |
| D+R− | 24 | 18 (23%) | 8 (14%) | |
| D−R+ | 26 | 17 (22%) | 7 (12%) | |
| D−R− | 34 | 16 (21%) | 18 (31%) | |
| Donor type | ||||
| MRD | 81 | 48 (62%) | 33 (57%) | .88 |
| MUD | 33 | 19 (24%) | 14 (24%) | |
| MMRD | 4 | 2 (3%) | 2 (3%) | |
| MMUD | 18 | 9 (12%) | 9 (16%) | |
| Cell source | ||||
| Bone marrow | 8 | 4 (5%) | 4 (7%) | .72 |
| Peripheral blood | 128 | 74 (95%) | 54 (93%) | |
| GVHD prophylaxis | ||||
| CsA-based | 82 | 48 (62%) | 34 (59%) | .87 |
| Tac-based | 48 | 27 (35%) | 21 (36%) | |
| Others | 6 | 3 (4%) | 3 (5%) | |
| Conditioning | ||||
| MAC | 64 | 35 (45%) | 29 (50%) | .60 |
| RIC | 72 | 43 (55%) | 29 (50%) | |
| With ATG | 70 | 43 (55%) | 27 (47%) | .39 |
| Without ATG | 66 | 35 (45%) | 31 (53%) | |
| aGVHD | ||||
| Grade 0-1 | 105 | 66 (85%) | 39 (67%) | .044 |
| Grade 2 | 23 | 8 (10%) | 15 (26%) | |
| Grade 3-4 | 8 | 4 (5%) | 4 (7%) |
| . | N . | Any HY-Ab seropositivity 3 mo post-HCT, n (%) . | HY-Ab seronegativity 3 mo post-HCT, n (%) . | P . |
|---|---|---|---|---|
| Total cohort | 136 | 78 (57%) | 58 (42%) | |
| Patient age, y | ||||
| <50 | 58 | 31 (40%) | 27 (47%) | .49 |
| ≥50 | 78 | 47 (60%) | 31 (53%) | |
| Donor age, y | ||||
| <50 | 92 | 50 (64%) | 42 (72%) | .46 |
| ≥50 | 43 | 27 (35%) | 16 (28%) | |
| Missing | 1 | |||
| Disease | ||||
| AML | 38 | 23 (29%) | 15 (26%) | .79 |
| ALL | 26 | 16 (21%) | 10 (17%) | |
| MDS, MPN | 19 | 12 (15%) | 7 (12%) | |
| Lymphoma | 48 | 25 (32%) | 23 (40%) | |
| Others | 5 | 2 (3%) | 3 (5%) | |
| Disease risk | ||||
| Standard | 105 | 57 (73%) | 48 (83%) | .22 |
| High | 31 | 21 (27%) | 10 (17%) | |
| CMV seropositivity | ||||
| D+R+ | 52 | 27 (35%) | 25 (43%) | .15 |
| D+R− | 24 | 18 (23%) | 8 (14%) | |
| D−R+ | 26 | 17 (22%) | 7 (12%) | |
| D−R− | 34 | 16 (21%) | 18 (31%) | |
| Donor type | ||||
| MRD | 81 | 48 (62%) | 33 (57%) | .88 |
| MUD | 33 | 19 (24%) | 14 (24%) | |
| MMRD | 4 | 2 (3%) | 2 (3%) | |
| MMUD | 18 | 9 (12%) | 9 (16%) | |
| Cell source | ||||
| Bone marrow | 8 | 4 (5%) | 4 (7%) | .72 |
| Peripheral blood | 128 | 74 (95%) | 54 (93%) | |
| GVHD prophylaxis | ||||
| CsA-based | 82 | 48 (62%) | 34 (59%) | .87 |
| Tac-based | 48 | 27 (35%) | 21 (36%) | |
| Others | 6 | 3 (4%) | 3 (5%) | |
| Conditioning | ||||
| MAC | 64 | 35 (45%) | 29 (50%) | .60 |
| RIC | 72 | 43 (55%) | 29 (50%) | |
| With ATG | 70 | 43 (55%) | 27 (47%) | .39 |
| Without ATG | 66 | 35 (45%) | 31 (53%) | |
| aGVHD | ||||
| Grade 0-1 | 105 | 66 (85%) | 39 (67%) | .044 |
| Grade 2 | 23 | 8 (10%) | 15 (26%) | |
| Grade 3-4 | 8 | 4 (5%) | 4 (7%) |
ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; ATG, anti-thymocyte globulin; CMV, cytomegalovirus; CsA, cyclosporine; D, donor CMV seropositivity; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MMRD, HLA-mismatched related donor; MMUD, HLA-mismatched unrelated donor; MPN, myeloproliferative neoplasm; R, recipient CMV seropositivity; MRD, HLA-matched related donor; MUD, HLA-matched unrelated donor; RIC, reduced intensity conditioning; Tac, tacrolimus.